Prosecutors have launched an investigation into Lee Woong-yeol, 63, chairman of the Kolon Group who is suspected of evading inheritance taxes.The Seoul Central District Prosecutors' Office has begun investigating Lee as the National Tax Service (NTS) has pressed a tax evasion charge against him.
The Kolon Group is preparing for the era of group management by a fourth-generation member from its founder’s family.Recently, Kolon Global and real estate-sharing service company Libeto Inc. have decided to establish Libeto Pte. Ltd. in Singapore. Kolon Global will hold a 65.2% stake in Libeto Pte.
The Kolon Group is striving to boost its competitiveness in the pharmaceutical and biotechnology business through cooperation with Korean and foreign partners. The group plans to become a mid-sized pharmaceutical company by signing co-promotion agreements with global pharmaceutical companies at home
Invossa, Korea's first gene therapy drug for knee osteoarthritis developed by the Kolon Group, made a foray into China, the largest market in Asia. Kolon signed a contract to supply 230 billion won (US$207 million) worth of Invossa to Henan Province in China for five years. The deal represents o
Invossa, South Korea’s first gene therapy for knee osteoarthritis developed by the Kolon Group, has crossed the final threshold for the phase 3 clinical trial in the US.Kolon TissueGene, an affiliate of the Kolon Group, announced on July 6 that the company has got approval of its use of the clinical
Kolon Group was given the green light for exporting Invossa, the world's first cell gene-based osteoarthritis drug, to the Middle East.Lee Woong-yeol, chairman of the Kolon Group, met with Sheikh Saud Bin Saqr Al Qasimi, current emir of Ras Al Khaimah, who was visiting Korea in Kolon One & Only